NanoViricides, Inc. (NYSE American: NNVC) has received regulatory approval from the local regulatory agency ACOREP in the Democratic Republic of Congo (DRC) to initiate a Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo ebolavirus outbreak and other Ebola viruses. The company has engaged Om Sai Clinical Research Private Limited as the contract research organization, with initial trial preparations already underway to accelerate first patient dosing. NanoViricides stated that sufficient quantities of NV-387 Oral Gummies are already in the DRC to begin the trial.
NV-387 is an investigational broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. The oral formulation could offer significant advantages in resource-limited outbreak settings compared with treatments requiring infusion. According to the World Health Organization, the current Bundibugyo ebolavirus outbreak in the DRC has resulted in 4,141 confirmed cases and 1,889 confirmed deaths as of Aug. 6, 2026.
The approval marks a critical step in addressing Ebola outbreaks, which often occur in regions with limited healthcare infrastructure. An oral treatment could simplify administration, reduce the need for trained medical personnel, and improve patient compliance. This is particularly important in the DRC, where access to intravenous therapies may be challenging.
NanoViricides' lead drug candidate, NV-387, is being developed for multiple viral infections, including RSV, COVID-19, Long COVID, Influenza, and other respiratory infections, as well as MPOX/Smallpox and Measles. The company is also developing NV-HHV-1 for Shingles. The Ebola trial is part of the company's broader strategy to expand its antiviral portfolio into neglected tropical diseases.
The company has a worldwide exclusive perpetual license to TheraCour's nanomedicine technology for several viruses, including Ebola and Marburg viruses. This trial will evaluate the safety and efficacy of NV-387 in patients with Ebola, with the goal of providing a new treatment option that is both effective and practical for outbreak settings.
For more information, visit the full press release at https://ibn.fm/2Pqu0.
